Qnomx
Qnomx AG is a Basel-based GenAI platform that automates variant interpretation and clinical report generation for NGS-based oncology diagnostic laboratories, integrating evidence from major clinical databases and deploying on top of existing tertiary analysis pipelines.
- Company typePrivate
- Founded2023
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Qnomx does
Qnomx AG is a Basel-based, privately held company founded in 2023 that has developed a GenAI platform for interpretation and clinical reporting in NGS-based oncology diagnostics. The product consists of two integrated modules — Qnomx Insight, which performs structured variant-level interpretation by consolidating evidence from OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, ESM, and PubMed into patient-specific draft annotations with traceable reasoning — and Qnomx Report, which transforms those structured interpretations into configurable, multilingual, clinician-ready reports with agentic chat for live editing. The platform deploys on top of existing tertiary analysis pipelines (Sophia Genetics, QIAGEN/QCI, VarSome) without disturbing validated upstream processes, and is positioned for IVDR Class C and EU AI Act compliance with ISO 27001 certification already achieved and ISO 13485, IVDR-C, and MDR-I certifications in progress.
The company targets oncology diagnostic laboratories scaling NGS-based cancer testing, with named customers and evaluation partners including Vall d'Hebron Research Institute (Spain), Labor Becker MVZ (Germany), Praava (Bangladesh), and GenCell (Argentina). Qnomx generates revenue through enterprise software licensing on a subscription basis, sold via direct field sales and an Early Access Programme, and is pursuing an 18-24 month clinical performance study in pediatric oncology with Vall d'Hebron to support its regulatory pathway. Total disclosed funding to date is approximately €1.7M in pre-Seed (April 2025, lead Heal Capital) plus an earlier 2023 seed-class round, the entity was incubated by CGC Genomics, and headcount remains in the 1-10 range, indicating an early-commercial-stage company whose scaling is gated primarily by regulatory certification rather than demand.
Qnomx firmographics
Firmographics- Name
- Qnomx
- Legal name
- Qnomx AG
- Website
- https://qnomx.ai
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Qnomx AG is a Basel-based GenAI platform that automates variant interpretation and clinical report generation for NGS-based oncology diagnostic laboratories, integrating evidence from major clinical databases and deploying on top of existing tertiary analysis pipelines.
- Ownership category
- akta.pro rank
Qnomx industry classification
Industry- Product category
- Clinical Genomics Software
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
Keywords
Where Qnomx is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Qnomx business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Software Platform Licensing: Qnomx generates revenue through software platform licensing to oncology diagnostic laboratories. The platform is offered as an integrated solution (Qnomx Insight for interpretation and Qnomx Report for reporting) that labs deploy within their existing workflows. Revenue appears to be subscription-based with enterprise licensing terms.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Qnomx product offering
Product offeringCore offering
Qnomx develops a GenAI platform for NGS-based cancer genome interpretation, consisting of two integrated modules. Qnomx Insight performs structured variant-level interpretation by consolidating evidence from leading clinical, population, and functional databases (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, PubMed) into patient-specific draft annotations. Qnomx Report transforms these structured interpretations into standardized, clinician-ready clinical reports following lab-configurable content standards, supporting multilingual output and agentic chat editing. The platform is deployed on top of existing tertiary analysis pipelines and targets IVDR Class C and EU AI Act compliance.
Product overview
Qnomx is a GenAI platform for NGS-based cancer genome interpretation, consisting of two integrated modules: Qnomx Insight handles structured variant-level interpretation by consolidating evidence from multiple clinical databases (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, PubMed) into patient-specific draft annotations, while Qnomx Report transforms these structured interpretations into clinician-ready clinical reports with configurable standards, multilingual support, and agentic chat editing capabilities. The platform operates after variant filtering and before clinical sign-off, reducing expert workload per NGS case by up to 85%.
Differentiator
Problem solved
Functional benefit
Products and services
- Qnomx Insight Structured variant-level interpretation module that consolidates evidence across leading clinical, population, and functional sources (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, ESMP, PubMed) in the context of each patient. Filters and prioritises variants straight from VCF files, drafts patient-specific annotations from traceable evidence bases, and shows reasoning, confidence, and agreement across sources for reviewable variant-level annotations.
- Qnomx Report
Quantifiable outcome
- Reduces expert workload per NGS case by up to 85%
- +2 more outcomes
Companies that use Qnomx
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
Qnomx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration11 records
AI capability5 records
Feature4 records
Qnomx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Vall d'Hebron Institute of ResearchcoreBarcelona-based research institute collaborating on an 18-24 month clinical performance study to evaluate Qnomx's AI-assisted summarization platform in pediatric oncology. Study launched March 2026.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Qnomx competitors and assessment
Company assessmentBroad incumbents
- SOPHiA GENETICS: Established NGS tertiary-analysis platform serving clinical genomics labs worldwide. Qnomx explicitly integrates with SOPHiA's stack as a value-added AI layer, so SOPHiA is both a partner and the most likely incumbent to internalize similar AI features.
- QIAGEN (Digital Insights / QCI): Major provider of clinical genomics interpretation software (QCI) used by oncology labs. Like SOPHiA, QCI is a confirmed Qnomx integration partner and a credible threat if it ships first-party AI interpretation.
- Tempus Labs: AI-driven precision medicine company with broad oncology focus, including NGS interpretation and clinical reporting. Much larger and broader than Qnomx, but addresses overlapping oncologist and lab-customer pain points.
- Caris Life Sciences: Oncology diagnostics and precision medicine company using molecular profiling and AI to support treatment decisions. Broader scope than Qnomx but overlaps on AI-assisted oncology interpretation and reporting.
- Foundation Medicine (Roche): Industry-leading molecular genomics profiling and interpretation for oncology, owned by Roche. Sets the bar for evidence-based cancer variant interpretation and report generation that Qnomx must differentiate against.
Direct peers
- Saphetor (VarSome): Clinical variant interpretation platform widely used by diagnostic labs, including in oncology. Overlaps directly with Qnomx Insight on variant annotation and clinical interpretation, though Qnomx adds GenAI-driven narrative generation.
- Fabric Genomics: AI-driven clinical genomics interpretation platform used in hereditary disease and oncology. Closest direct competitor in clinical interpretation software with a comparable hospital-lab go-to-market motion.
- Congenica: Clinical genomics decision-support platform for rare disease and cancer, selling into hospital labs. Comparable in customer segment, regulatory positioning, and emphasis on automated clinical interpretation.
Emerging players
- PathAI: AI platform for pathology diagnostics with regulated, evidence-driven positioning. Adjacent rather than directly overlapping (pathology vs. NGS), but a useful comp for AI-in-regulated-diagnostics go-to-market.
- Owkin: AI-for-clinical-research and diagnostics company with European roots and regulated-AI focus. Comparable in mission (AI applied to clinical decision-making) and in building evidence-grade products for hospitals and pharma.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Qnomx social profiles
Digital presenceQnomx compliance and trust
Trust signalCompliance7 records
Qnomx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qnomx leadership team
Management profileNumber of profiles
Profiles4 records
Qnomx funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qnomx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qnomx
What does Qnomx do?
Qnomx develops a GenAI platform for NGS-based cancer genome interpretation, consisting of two integrated modules. Qnomx Insight performs structured variant-level interpretation by consolidating evidence from leading clinical, population, and functional databases (OncoKB, COSMIC, ClinVar, gnomAD, Ensembl VEP, UniProtKB/ProtVar, REVEL, PubMed) into patient-specific draft annotations. Qnomx Report transforms these structured interpretations into standardized, clinician-ready clinical reports following lab-configurable content standards, supporting multilingual output and agentic chat editing. The platform is deployed on top of existing tertiary analysis pipelines and targets IVDR Class C and EU AI Act compliance.
Is Qnomx a public or private company?
Qnomx is a private company. It is classified as venture growth investor backed and is currently operating.
When was Qnomx founded?
Qnomx was founded in 2023. It employs 1 to 10 people.
Where is Qnomx based?
Qnomx is headquartered in Basel, Switzerland, in the Europe region.
How does Qnomx make money?
One revenue line is on record: software Platform Licensing.
Who are Qnomx's main competitors?
Broad incumbents on record are SOPHiA GENETICS, QIAGEN (Digital Insights / QCI), Tempus Labs, Caris Life Sciences and Foundation Medicine (Roche). Direct peers are Saphetor (VarSome), Fabric Genomics and Congenica. Emerging players are PathAI and Owkin.
Does Qnomx have an API?
No public API is recorded for Qnomx.
What industry is Qnomx in?
Qnomx's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 54151 and its SIC code is 7372.